Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease

Peptides

Volumn 27, Issue 11, 2006, Pages 2919-2926

  Bousette, Nicolas ^a   Pottinger, Julia ^a   Ramli, Wisam ^a   Ohlstein, Eliot H ^b   Dhanak, Dashyant ^b   Douglas, Stephen A ^b   Giaid, Adel ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Collagen; Fibrosis; Myocardial infarction; Rat; Urotensin II

Indexed keywords

COLLAGEN TYPE 1; RECEPTOR BLOCKING AGENT; SB 611812; UNCLASSIFIED DRUG; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY LIGATION; DIASTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; FIBROSING ALVEOLITIS; HEART FUNCTION; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MALE; MITOSIS RATE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; GENE EXPRESSION PROFILING; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RATS; RATS, INBRED LEW; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; UROTENSINS; VENTRICULAR REMODELING;

ANIMALIA;

EID: 33750066365     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.06.011     Document Type: Article

References (21)

1. Ames R.S., Sarau H.M., Chambers, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat modal of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
3. Dhanak D, Knight SD. Sulfonamide derivative urotensin-II receptor antagonists, preparation, pharmaceutical compositions, and therapeutic use. PCT Int Appl WO 2,001,045,694 2001.
4. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
5. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136 (2002) 9-22
6. He Y.H., Hong J.M., Guo H.S., Wei J.R., Chen H., Zuo H.H., et al. Effects of urotensin II on cultured cardiac fibroblast proliferation and collagen type I mRNA expression. Di Yi Jun Yi Da Xue Xue Bao 24 (2004) 505-508 [Chinese]
7. Huang Y., Hunyor S.N., Jiang L., Kawaguchi O., Shirota K., Ikeda Y., et al. Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses. Am J Physiol Heart Circ Physiol 286 (2004) H2141-H2150
8. Kompa A.R., Thomas W.G., See F., Tzanidis A., Hannan R.D., and Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25 (2004) 1783-1788
9. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
10. Marijianowski M.M., Teeling P., Mann J., and Becker A.E. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 25 (1995) 1263-1272
11. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
12. Nishikawa N., Masuyama T., Yamamoto K., et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 38 (2001) 1539-1545
13. Rakowski E., Hassan G.S., Dhanak D., Ohlstein E.H., Douglas S.A., and Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol 39 (2005) 785-791
14. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
15. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
16. Saetrum Opgaard O., Nothacker H., Ehlert F.J., and Krause D.N. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406 (2000) 265-271
17. Saito T., Hu F., Tayara L., Fahas L., Shennib H., and Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 283 (2002) H339-H345
18. Tasaki K., Hori M., Ozaki H., Karaki H., and Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci 94 (2004) 376-383
19. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
20. Wang H., Mehta J.L., Chen K., Zhang X., and Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 44 (2004) 577-581
21. Wei S., Chow L.T., and Sanderson J.E. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 36 (2000) 276-281